SCHEMBL5164835

SCHEMBL5164835

O=c1[nH]nc(CNc2ccc(Oc3ccccc3)cc2)c2ccccc12

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.77
▸ GAA P10253 2/20 0.77
▸ SMN1; SMN2 Q16637 3/20 0.72
▸ HTT P42858 2/20 0.72
▸ KMT2A Q03164 3/20 0.70
▸ KDM4E B2RXH2 2/20 0.70
▸ MEN1 O00255 1/20 0.70
▸ ALDH1A1 P00352 1/20 0.70
▸ THRB P10828 1/20 0.70
▸ RECQL P46063 1/20 0.70
▸ BLM P54132 1/20 0.70
▸ HIF1A Q16665 1/20 0.52
▸ LMNA P02545 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.50
▸ PARP1 P09874 1/20 0.50
▸ AR P10275 1/20 0.50
▸ PRMT5 O14744 2/20 0.49
▸ POLB P06746 2/20 0.48
▸ FFAR1 O14842 1/20 0.46
▸ FFAR4 Q5NUL3 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5165966 0.87 MAPT (0.78) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL5161752 0.87 MAPT (1.00) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL5165083 0.84 HTT (1.00) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL5160240 0.82 MAPT (1.00) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL5160111 0.82 MAPT (0.75) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL5162135 0.78 MAPT (0.68) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL6326092 0.76 MAPT (0.61) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL6281157 0.75 MAPT (0.64) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL12955545 0.74 PARP1 (0.70) LMNAPARP1AR
SCHEMBL13858810 0.72 KDM4E (0.66) MAPTGAASMN1; SMN2HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1231982-B1 USE OF PHTHALAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES ABBOTT GMBH & CO KG (DE) 2007-03-21 — — EP disclosed
US-6903098-B1 Use of phthalazine derivatives ABBOTT GMBH & CO. (DE) 2005-06-07 — — US disclosed
Send feedback